Birchview Capital LP Buys Shares of 60,000 Immunome, Inc. $IMNM

Birchview Capital LP purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) during the second quarter, Holdings Channel.com reports. The fund purchased 60,000 shares of the company’s stock, valued at approximately $558,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in Immunome in the 2nd quarter valued at about $98,000. Whalen Wealth Management Inc. bought a new position in Immunome during the second quarter worth about $128,000. Creative Planning purchased a new position in shares of Immunome in the second quarter worth about $167,000. Teacher Retirement System of Texas raised its position in shares of Immunome by 6.8% in the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after purchasing an additional 1,188 shares during the period. Finally, Voya Investment Management LLC lifted its stake in shares of Immunome by 21.2% during the 1st quarter. Voya Investment Management LLC now owns 18,905 shares of the company’s stock valued at $127,000 after buying an additional 3,305 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on IMNM shares. Evercore ISI assumed coverage on shares of Immunome in a report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective for the company. Truist Financial started coverage on Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 price target for the company. Guggenheim reiterated a “buy” rating and issued a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of Immunome in a report on Friday, November 7th. Finally, Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Immunome Stock Up 0.4%

Immunome stock opened at $19.57 on Friday. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -6.63 and a beta of 2.17. The business has a 50-day simple moving average of $16.94 and a 200 day simple moving average of $12.24. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $20.80.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.